Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 805

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 805
---
415 | ​ | $ |     72 | ​ | $ |      — |
| Clinical compound revenue                    | ​ | ​                       |      ​ | ​ | ​ |      ​ | ​ | ​ |      ​ |
| CSL Vifor* (difelikefalin injection)         | ​ | $                       |      — | ​ | $ |      — | ​ | $ |    361 |
| Maruishi                                     | ​ | ​                       |    165 | ​ | ​ |      — | ​ | ​ |     37 |
| Total clinical compound revenue              | ​ | $                       |    165 | ​ | $ |      — | ​ | $ |    398 |
| Other revenue (non-cash)                     | ​ | ​                       |      ​ | ​ | ​ |      ​ | ​ | ​ |      ​ |
| CSL Vifor (Kapruvia ex U.S.)                 | ​ | $                       |    284 | ​ | $ |      — | ​ | $ |      — |
| Maruishi                                     | ​ | ​                       |    415 | ​ | ​ |      — | ​ | ​ |      — |
| Total other revenue                          | ​ | $                       |    699 | ​ | $ |      — | ​ | $ |      — |

_____________________________

* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.

Collaborative revenue

Beginning in April 2022, the Company began recording its share of the profit generated by KORSUVA injection sales by CSL Vifor to third parties in the United States. Under the license agreements with CSL Vifor, KORSUVA injection net sales are calculated by CSL Vifor which are net of discounts, rebates, and allowances. These amounts include the use of estimates and judgments, which could be adjusted based on actual results in the future. The Company records its share of the net profits from the sales of KORSUVA injection in the United States on a net basis (since the Company is not the primary obligor and does not retain inventory risk) and presents the revenue earned each period as collaborative revenue. During the years ended December 31, 2023 and 2022, the Company recorded$ 12,397and